Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

A Phase I Study of CD19-Targeted 19(T2)28z1xx CAR T Cells in Adult Patients with Relapsed or Refractory B-Cell Malignancies

Jae H. Park, MD, Isabelle Riviere, PhD, Devanjan S. Sikder, Vladimir P. Bermudez, Brigitte Senechal, Xiuyan Wang, PhD, Thomas H. Auchincloss, Claudia Diamonte, RN, Elizabeth Halton, NP-BC AOCNP, M. Lia Palomba, MD, Renier J. Brentjens, MD PhD, Michel Sadelain, MD PhD

Blood (2020) 136 (Supplement 1): 43–44.

https://doi.org/10.1182/blood-2020-143088

Published: 2020

Journal Articles

NOTCH and CAR Signaling Control T Cell Lineage Commitment from Pluripotent Stem Cells

Sjoukje van der Stegen, PhD, Pieter Lindenbergh, Roseanna Petrovic, PhD, Benjamin Whitlock, PhD, Raedun Clarke, PhD, Bahram Valamehr, PhD, Isabelle Riviere, PhD, Michel Sadelain, MD PhD

Blood (2020) 136 (Supplement 1): 30.

https://doi.org/10.1182/blood-2020-142894

Published: 2020

Journal Articles

FT819: Translation of Off-the-Shelf TCR-Less Trac-1XX CAR-T Cells in Support of First-of-Kind Phase I Clinical Trial

Blood (2019) 134 (Supplement_1): 4434.

https://doi.org/10.1182/blood-2019-130584

Published: 2019

Journal Articles

Clinical Factors Associated with Improved Survival Following Allogeneic HSCT after CD19 CAR Therapy in Adult Patients with Relapsed B-ALL

Jae H. Park, MD, Jessica Flynn, BS, Mithat Gonen, Yvette Bernal, MS, Claudia Diamonte, RN, Elizabeth Halton, NP-BC AOCNP, Xiuyan Wang, PhD, Isabelle Riviere, PhD, Michel Sadelain, MD PhD, Renier J. Brentjens, MD PhD

Blood (2019) 134 (Supplement_1): 1348.

https://doi.org/10.1182/blood-2019-129343

Published: 2019

Journal Articles

Pluripotent Cell-Derived Off-the-Shelf TCR-Less CAR-Targeted Cytotoxic T Cell Therapeutic for the Allogeneic Treatment of B Cell Malignancies

Blood (2018) 132 (Supplement 1): 4546.

https://doi.org/10.1182/blood-2018-99-116843

Published: 2018

Journal Articles

Clinical Responses and Pharmacokinetics of MCARH171, a Human-Derived Bcma Targeted CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma: Final Results of a Phase I Clinical Trial

Blood (2018) 132 (Supplement 1): 959.

https://doi.org/10.1182/blood-2018-99-119717

Published: 2018

Journal Articles

Intestinal Microbiota Composition Prior to CAR T Cell Infusion Correlates with Efficacy and Toxicity

Blood (2018) 132 (Supplement 1): 3492.

https://doi.org/10.1182/blood-2018-99-118628

Published: 2018

Journal Articles

CAR T Cell Therapy Targeting G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D), a Novel Target for the Immunotherapy of Multiple Myeloma

Blood (2018) 132 (Supplement 1): 589.

https://doi.org/10.1182/blood-2018-99-110471

Published: 2018

Journal Articles

A Phase I First-in-Human Clinical Trial of CD19-Targeted 19-28z/4-1BBL "Armored" CAR T Cells in Patients with Relapsed or Refractory NHL and CLL Including Richter's Transformation

Jae H. Park, MD, Maria Lia Palomba, MD, Connie Lee Batlevi, MD, Isabelle Riviere, PhD, Xiuyan Wang, PhD, Brigitte Senechal, PhD, Richard R. Furman, MD, Yvette Bernal, MS, Malloury Hall, BA, John Pineda, RN, Claudia Diamonte, RN, Elizabeth Halton, NP-BC AOCNP, Renier J. Brentjens, MD PhD, Michel Sadelain, MD PhD

Blood (2018) 132 (Supplement 1): 224.

https://doi.org/10.1182/blood-2018-99-117737

Published: 2018

Journal Articles

Safety and Efficacy Trial of Escalation of Plerixafor for Mobilization of CD34+ Hematopoietic Progenitor Cells (HPCs) for Globin Gene Transfer in Patients with Sickle Cell Disease

Farid Boulad, MD, Tsiporah B. Shore, MD, Koen Van Besien, MD PhD, Danielle Guarneri, June Greenberg, RN, Caterina Minniti, MD, Sylvie wiener Fedus, Fabiana Perna, MD, Xiuyan Wang, PhD, Isabelle Riviere, PhD, Michel Sadelain, MD PhD, Patricia Shi, MD

Blood (2017) 130 (Supplement 1): 3531.

https://doi.org/10.1182/blood.V130.Suppl_1.3531.3531

Published: 2017

Journal Articles

Development and Evaluation of a Human Single Chain Variable Fragment (scFv) Derived Bcma Targeted CAR T Cell Vector Leads to a High Objective Response Rate in Patients with Advanced MM

Blood (2017) 130 (Supplement 1): 742.

https://doi.org/10.1182/blood.V130.Suppl_1.742.742

Published: 2017

Journal Articles

Generation of Clonal Antigen Specific CD8αβ + Cytotoxic T Lymphocytes from Renewable Pluripotent Stem Cells for Off-the-Shelf T Cell Therapeutics

Sjoukje Van Der Stegen, PhD, Raedun Clarke, PhD, Jorge Mansilla - Soto, PhD, Edwin Ortiz, Chia-Wei Chang, Jeff Sasaki, Tom Lee, PhD, Weijie Lan, PhD, Daniel Shoemaker, PhD, Isabelle Riviere, PhD, Bahram Valamehr, PhD, Michel Sadelain, MD PhD

Blood (2017) 130 (Supplement 1): 163.

https://doi.org/10.1182/blood.V130.Suppl_1.163.163

Published: 2017

Journal Articles

High Dose Cyclophosphamide and Pre-Treatment Disease Burden Dictate Response and Survival in a Multicenter Clinical Trial Using CD19-Specific CAR T Cells for Relapsed/Refractory B-ALL

Blood (2017) 130 (Supplement 1): 1326.

https://doi.org/10.1182/blood.V130.Suppl_1.1326.1326

Published: 2017

Journal Articles

Implications of Concurrent Ibrutinib Therapy on CAR T-Cell Manufacturing and Phenotype and on Clinical Outcomes Following CD19-Targeted CAR T-Cell Administration in Adults with Relapsed/Refractory CLL

Mark Blaine Geyer, MD, Jae H. Park, MD, Isabelle Riviere, PhD, Brigitte Senechal, PharmD, PhD, Xiuyan Wang, PhD, Terence J. Purdon, Michel W. Sadelain, MD PhD, Renier J. Brentjens, MD PhD

Blood (2016) 128 (22): 58.

https://doi.org/10.1182/blood.V128.22.58.58

Published: 2016

Journal Articles

Implications of Minimal Residual Disease Negative Complete Remission (MRD-CR) and Allogeneic Stem Cell Transplant on Safety and Clinical Outcome of CD19-Targeted 19-28z CAR Modified T Cells in Adult Patients with Relapsed, Refractory B-Cell ALL

Jae H Park, MD, Isabelle Riviere, PhD, Xiuyan Wang, PhD, Yvette Bernal, MS, Terence Purdon, Elizabeth Halton, RN, MS, ANP, Yongzeng Wang, PhD, Kevin J. Curran, MD, Craig S. Sauter, MD, Michel Sadelain, MD PhD, Renier J. Brentjens, MD PhD

Blood (2015) 126 (23): 682.

https://doi.org/10.1182/blood.V126.23.682.682

Published: 2015

Journal Articles

Multi-Center Clinical Trial of CAR T Cells in Pediatric/Young Adult Patients with Relapsed B-Cell ALL

Blood (2015) 126 (23): 2533.

https://doi.org/10.1182/blood.V126.23.2533.2533

Published: 2015

Journal Articles

Chimeric Antigen Receptor (CAR) T Cells Targeting the CD19 Antigen for the Treatment of Pediatric Relapsed B Cell ALL

Kevin J. Curran, MD, Isabelle Riviere, PhD, Rachel Kobos, MD, Nancy A. Kernan, MD, Farid Boulad, MD, Susan E. Prockop, MD, Andromachi Scaradavou, MD, Thomas M. Renaud, MD, Neerav Shukla, MD, Peter G Steinherz, MD, Jae H Park, MD, Craig S. Sauter, MD, Richard J O'Reilly, MD, Michel Sadelain, MD PhD, Renier J. Brentjens, MD PhD

Blood (2014) 124 (21): 3716.

https://doi.org/10.1182/blood.V124.21.3716.3716

Published: 2014

Journal Articles

Interim Safety Analysis: a Phase I Trial of High Dose Therapy and Autologous Stem Cell Transplantation Followed By Infusion of Chimeric Antigen Receptor Modified T-Cells (19-28z CAR-T) Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma (B-NHL)

Craig S. Sauter, MD, Isabelle Riviere, PhD, Yvette J Bernal, MS, Xiuyan Wang, PhD, Terence J. Purdon, Sarah Yoo, Craig H Moskowitz, MD, Sergio Giralt, MD, Matthew J Matasar, MD MS, Kevin J. Curran, MD, Jae H Park, MD, Michel Sadelain, MD PhD, Renier J. Brentjens, MD PhD

Blood (2014) 124 (21): 677.

https://doi.org/10.1182/blood.V124.21.677.677

Published: 2014

Journal Articles

CD19-Targeted 19-28z CAR Modified Autologous T Cells Induce High Rates of Complete Remission and Durable Responses in Adult Patients with Relapsed, Refractory B-Cell ALL

Jae H Park, MD, Isabelle Riviere, PhD, Xiuyan Wang, PhD, Yvette J Bernal, MS, Sarah Yoo, Terrence Purdon, Elizabeth Halton, RN, MS, ANP, Hilda Quintanilla, RN, MS, ANP, Kevin J. Curran, MD, Craig S. Sauter, MD, Marco L Davila, MD PhD, Michel Sadelain, MD PhD, Renier J. Brentjens, MD PhD

Blood (2014) 124 (21): 382.

https://doi.org/10.1182/blood.V124.21.382.382

Published: 2014

Journal Articles

Safe and Effective Re-Induction Of Complete Remissions In Adults With Relapsed B-ALL Using 19-28z CAR CD19-Targeted T Cell Therapy

Blood (2013) 122 (21): 69.

https://doi.org/10.1182/blood.V122.21.69.69

Published: 2013

NARROW

A Phase I Study of CD19-Targeted 19(T2)28z1xx CAR T Cells in Adult Patients with Relapsed or Refractory B-Cell Malignancies

NOTCH and CAR Signaling Control T Cell Lineage Commitment from Pluripotent Stem Cells

FT819: Translation of Off-the-Shelf TCR-Less Trac-1XX CAR-T Cells in Support of First-of-Kind Phase I Clinical Trial

Clinical Factors Associated with Improved Survival Following Allogeneic HSCT after CD19 CAR Therapy in Adult Patients with Relapsed B-ALL

Pluripotent Cell-Derived Off-the-Shelf TCR-Less CAR-Targeted Cytotoxic T Cell Therapeutic for the Allogeneic Treatment of B Cell Malignancies

Clinical Responses and Pharmacokinetics of MCARH171, a Human-Derived Bcma Targeted CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma: Final Results of a Phase I Clinical Trial

Intestinal Microbiota Composition Prior to CAR T Cell Infusion Correlates with Efficacy and Toxicity

CAR T Cell Therapy Targeting G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D), a Novel Target for the Immunotherapy of Multiple Myeloma

A Phase I First-in-Human Clinical Trial of CD19-Targeted 19-28z/4-1BBL "Armored" CAR T Cells in Patients with Relapsed or Refractory NHL and CLL Including Richter's Transformation

Safety and Efficacy Trial of Escalation of Plerixafor for Mobilization of CD34+ Hematopoietic Progenitor Cells (HPCs) for Globin Gene Transfer in Patients with Sickle Cell Disease

Development and Evaluation of a Human Single Chain Variable Fragment (scFv) Derived Bcma Targeted CAR T Cell Vector Leads to a High Objective Response Rate in Patients with Advanced MM

Generation of Clonal Antigen Specific CD8αβ + Cytotoxic T Lymphocytes from Renewable Pluripotent Stem Cells for Off-the-Shelf T Cell Therapeutics

High Dose Cyclophosphamide and Pre-Treatment Disease Burden Dictate Response and Survival in a Multicenter Clinical Trial Using CD19-Specific CAR T Cells for Relapsed/Refractory B-ALL

Implications of Concurrent Ibrutinib Therapy on CAR T-Cell Manufacturing and Phenotype and on Clinical Outcomes Following CD19-Targeted CAR T-Cell Administration in Adults with Relapsed/Refractory CLL

Implications of Minimal Residual Disease Negative Complete Remission (MRD-CR) and Allogeneic Stem Cell Transplant on Safety and Clinical Outcome of CD19-Targeted 19-28z CAR Modified T Cells in Adult Patients with Relapsed, Refractory B-Cell ALL

Multi-Center Clinical Trial of CAR T Cells in Pediatric/Young Adult Patients with Relapsed B-Cell ALL

Chimeric Antigen Receptor (CAR) T Cells Targeting the CD19 Antigen for the Treatment of Pediatric Relapsed B Cell ALL

Interim Safety Analysis: a Phase I Trial of High Dose Therapy and Autologous Stem Cell Transplantation Followed By Infusion of Chimeric Antigen Receptor Modified T-Cells (19-28z CAR-T) Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma (B-NHL)

CD19-Targeted 19-28z CAR Modified Autologous T Cells Induce High Rates of Complete Remission and Durable Responses in Adult Patients with Relapsed, Refractory B-Cell ALL

Safe and Effective Re-Induction Of Complete Remissions In Adults With Relapsed B-ALL Using 19-28z CAR CD19-Targeted T Cell Therapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only